Transgenic mice deficient for the p53 gene were reported to frequently develop angiosarcoma (AS), suggesting that alterations in the gene are associated with tumorigenesis of AS. However, little is known about genetic changes, including p53 gene alterations, in human AS because of its rarity. We ana
Cloning of feline p53 tumor-suppressor gene and its aberration in hematopoietic tumors
β Scribed by Masaru Okuda; Akiko Umeda; Tadashi Sakai; Takashi Ohashi; Yasuyuki Momoi; Hwa-Young Youn; Toshihiro Watari; Ryo Goitsuka; Hajimc Tsujtmoto; Atsuhiko Hasegawa
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- French
- Weight
- 686 KB
- Volume
- 58
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Alterations of the p53 tumor-suppressor gene have been observed in a variety of human and mouse tumors. For investigation of the role of this gene in tumors of cats, feline p53 cDNA was molecularly cloned from a feline lymph-node cDNA library. The cloned cDNA (FF53) contained the whole open reading frame of p53 gene encoding 386 amino acids. The amino-acid sequence of the feline p53 gene showed 82.1% and 74.9% similarities with those of the human and mouse counterparts, respectively, and had structural characteristics in common with the p53 genes of several other species. Aberrations of the p53 gene were investigated by RT-PCR and single-strand conformation polymorphism analyses. Of I0 primary hematopoietic tumors and 3 lymphoma cell lines examined, one lymphoma and one lymphoma cell line had a point mutation of the p53 gene, resulting in single amino-acid substitutions. 0 IVY4 M.lleb-1 ISS. In
π SIMILAR VOLUMES
Loss of heterozygosity at 4 tumor-suppressor gene loci (pS3, apc, mcc and Rb) was investigated using polymerase chain reactions, in 49 esophageal squamous-cell carcinoma specimens from patients who had undergone curative resection. Mutations in the p53 gene within exons 5 to 8 were also examined. LO
## Abstract Drug resistance remains a key obstacle to successful cancer treatment. The implementation of pharmacogenomics is widely proclaimed as a route to revolutionize the face of cancer therapy. Here we discuss the pharmacogenomics of the p53 tumor suppressor and its role in cancer chemosensiti
The prognostic significance and nature of p53 dysfunction in ovarian carcinoma is unclear. The relation between p53 overexpression, p53 mutations, and their effects on overall survival in primary ovarian carcinoma is explored. ## METHODS. Tumor specimens from 171 consecutive epithelial ovarian ca
Human hepatocellular carcinomas from patients in Britain, an area of low prevalence of hepatocellular carcinoma and low dietary exposure to aflatoxin B,, were analyzed for mutations in the p53 tumorsuppressor gene. Abnormalities in the pS3 gene were detected in 2 of 19 hepatocellular carcinomas by p